US FDA places clinical hold on Regenxbio's gene therapy trials
I'm PortAI, I can summarize articles.
Jan 28 (Reuters) - Regenxbio ( RGNX ) said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its experimental gene therapy programs for rare childhood diseases after a brain tumor was found in one treated patient. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber)
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments